These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21701624)

  • 21. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates for steroid-induced osteoporosis.
    Allen CS; Yeung JH; Vandermeer B; Homik J
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD001347. PubMed ID: 27706804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2002 Jul; 3(7):1007-9. PubMed ID: 12083999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.
    Nakamura Y; Shimizu T; Asano T; Shimodan S; Ishizu H; Takahashi D; Takahata M; Iwasaki N
    J Bone Miner Metab; 2021 Sep; 39(5):824-832. PubMed ID: 33821302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis.
    Liu M; Guo L; Pei Y; Li N; Jin M; Ma L; Liu Y; Sun B; Li C
    Int J Clin Exp Med; 2015; 8(3):3855-61. PubMed ID: 26064284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
    Pazianas M; Cooper C; Ebetino FH; Russell RG
    Ther Clin Risk Manag; 2010 Jul; 6():325-43. PubMed ID: 20668715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data.
    Miller PD
    Curr Med Res Opin; 2008 Jan; 24(1):107-19. PubMed ID: 18031594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.
    Lewiecki EM
    Core Evid; 2010 Jun; 4():13-23. PubMed ID: 20694061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of zoledronic acid in the management of osteoporosis.
    Maricic M
    Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence.
    Sim IeW; Ebeling PR
    Ther Adv Musculoskelet Dis; 2013 Oct; 5(5):259-67. PubMed ID: 24101947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates.
    Fobelo Lozano MJ; Sánchez-Fidalgo S
    Eur J Hosp Pharm; 2019 Jan; 26(1):4-9. PubMed ID: 31157088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.
    Hamdy RC
    Drug Des Devel Ther; 2010 Nov; 4():321-35. PubMed ID: 21151620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.
    Giusti A
    J Bone Miner Metab; 2014 Nov; 32(6):606-15. PubMed ID: 24748165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application.
    Cole RE; Harris ST
    Medscape J Med; 2009; 11(1):12. PubMed ID: 19295933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.
    Kimmel DB
    J Dent Res; 2007 Nov; 86(11):1022-33. PubMed ID: 17959891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.
    Rizzoli R
    Ther Adv Musculoskelet Dis; 2010 Feb; 2(1):3-16. PubMed ID: 22870433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.